Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Litha, Jaison"'
Autor:
Xavier Pivot, Alexey Georgievitch Manikhas, Volodymyr Shamrai, Giorgi Dzagnidze, Hwoei Fen Soo Hoo, Viriya Kaewkangsadan, Fausto Petrelli, Cristian Villanueva, Jamie Kim, Sumita Pradhan, Litha Jaison, Peggy Feyaerts, Leonard Kaufman, Marie-Paule Derde, Filip Deforce, David G. Cox
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background The TROIKA trial established that HD201 and trastuzumab were equivalent in terms of primary endpoints (total pathological complete response) following neoadjuvant treatment. The objective of the present analysis was to compare sur
Externí odkaz:
https://doaj.org/article/6c8d15b8875948eb849c5e19e8288c4d
Autor:
Martin Demarchi, Pierre Coliat, Kristi Mclendon, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Ang, Litha Jaison, Filip Deforce, Marie Paule Derde, Michael Jinwoo Kim, Lisa Soyeon Park, Alexandre Detappe, Xavier Pivot
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 4, Pp n/a-n/a (2021)
Abstract Prestige Biopharma Ltd (Singapore) has developed HD201, a proposed biosimilar to reference product trastuzumab. As a part of the stepwise approach to ensure comparability between the biosimilar candidate and the reference medicinal product,
Externí odkaz:
https://doaj.org/article/81e0d5aa8ebc42d8a35ba3783ef70e13
Autor:
Michael Jinwoo Kim, Peggy Feyaerts, Marie Paule Derde, Alexandre Detappe, Litha Jaison, Felicia Ang, Filip Deforce, Jocelyn hii, Martin Demarchi, Lisa Soyeon Park, Xavier Pivot, Kristi Mclendon, Pierre Coliat
Publikováno v:
Pharmacology Research & Perspectives. 9
Prestige Biopharma Ltd (Singapore) has developed HD201, a proposed biosimilar to reference product trastuzumab. As a part of the stepwise approach to ensure comparability between the biosimilar candidate and the reference medicinal product, a phase I
Autor:
Kedar Diwakar Mandakhalikar, Sang Seok Koh, Seong-Yun Jeong, Deborah Moshinsky, Peggy Feyaerts, Ratna Karuna, Jamie Kim, Litha Jaison, Sumita Pradhan, Yeon Jeong Kim, Jin Park
Publikováno v:
Journal of Clinical Oncology. 40:e16274-e16274
e16274 Background: PAUF has been shown to induce PC cell proliferation, angiogenesis and evasion of immune surveillance, thereby promoting tumour progression and metastasis. PBP1510, a novel humanized IgG1 mAb developed by Prestige Biopharma Limited,
Autor:
Xavier, Pivot, M A, Georgievich, Volodymyr, Shamrai, Giorgi, Dzagnidze, Hwoei Fen, Soo Hoo, Viriya, Kaewkangsadan, Fausto, Petrelli, Cristian, Villanueva, Lipatov O, Nikolaevich, Jocelyn, Hii, Jamie, Kim, Sumita, Pradhan, Litha, Jaison, Peggy, Feyaerts, Leonard, Kaufman, Marie-Paule, Derde, Ghislain M C, Bonamy, Filip, Deforce, David G, Cox
Publikováno v:
JAMA Oncol
The drug HD201 is a biosimilar candidate for breast cancer treatment as the reference trastuzumab.To compare the efficacy of HD201 with referent trastuzumab.This randomized clinical trial (TROIKA) included 502 women with ERBB2-positive early breast c